Drug intelligence / Profile preview

ST13

Development stage: Preclinical
Modality: Small Molecules
Administration: Topical

Overview

ST13 is a novel hydroxamate derivative and a pan-histone deacetylase (HDAC) inhibitor. It has demonstrated potent growth-inhibitory effects in various leukemia cell lines (HL60, Kasumi-1, NB-4, THP-1, K562, U937, Jurkat) and primary acute myeloid leukemia (AML) blasts at low micromolar concentrations. Its mechanism involves increasing the acetylation of histones H3 and H4, as well as α-tubulin.

Targets

HDAC1 (Histone Deacetylase 1)

Beyond the preview

Go deeper on ST13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST13.

Explore the full profile